UNASSIGNED: Our search encompassed PubMed, Medline, Cochrane, and Embase databases, with a focus on evaluating study quality. Data extraction was conducted from randomized controlled trials (RCTs), and RevMan 5.3 facilitated result analysis.
UNASSIGNED: Combining trebananib with other drugs extended progression-free survival (PFS) [HR 0.81, (95%CI: 0.65, 0.99), p = 0.04] and overall survival (OS) [HR 0.88, (95%CI: 0.79, 1.00), p = 0.04] in ovarian cancer patients. Ovarian cancer patients exhibited a higher objective response rate (ORR) with trebananib compared to non-ovarian cancer cohorts. Moreover, the incorporation of trebananib into the standard treatment regimen for malignant tumors did not significantly elevate drug-related adverse events [RR 1.05, (95% CI: 1.00, 1.11), p = 0.05].
UNASSIGNED: Trebananib plus other drugs can improve the PFS, OS and ORR in patients with cancer, especially ovarian cancer. Our recommendation is to use trebananib plus other drugs to treat advanced cancer, and to continuously monitor and manage drug-related adverse events.
UNASSIGNED: PROSPERO (No. CRD42023466988).
■我们的搜索包括PubMed,Medline,科克伦,和Embase数据库,重点评估研究质量。数据提取来自随机对照试验(RCTs),和RevMan5.3促进了结果分析。
■将曲巴纳尼与其他药物联合使用可延长无进展生存期(PFS)[HR0.81,(95CI:0.65,0.99),p=0.04]和总生存率(OS)[HR0.88,(95CI:0.79,1.00),在卵巢癌患者中p=0.04。与非卵巢癌队列相比,卵巢癌患者使用trebanib表现出更高的客观反应率(ORR)。此外,在恶性肿瘤的标准治疗方案中加入曲巴那尼并没有显著增加药物相关的不良事件[RR1.05,(95%CI:1.00,1.11),p=0.05]。
■Trebanib加上其他药物可以改善PFS,癌症患者的OS和ORR,尤其是卵巢癌.我们的建议是使用trebanib和其他药物来治疗晚期癌症,并持续监测和管理与药物相关的不良事件。
■PROSPERO(编号:CRD42023466988)。